Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? Rachel S. Rosenberg ZandRachel S. Rosenberg ZandEleftherios P. Diamandis OriginalPaper Pages: 1 - 8
Framing of outcome and probability of recurrence: Breast cancer patients' choice of adjuvant chemotherapy (ACT) in hypothetical patient scenarios Christa ZimmermannCarla BaldoAnnamaria Molino OriginalPaper Pages: 9 - 14
Progression in MCF-7 breast cancer cell tumorigenicity: compared effect of FGF-3 and FGF-4 Amin HajitouChristophe DeroanneClaire-M. Calberg-Bacq OriginalPaper Pages: 15 - 28
Resection margin status in lumpectomy specimens of infiltrating lobular carcinoma Kien T. MaiHossein M. YazdiPhillip A. Isotalo OriginalPaper Pages: 29 - 33
Detection of microsatellite alterations in nipple discharge accompanied by breast cancer Michihiko MiyazakiYasuhiro TamakiMorito Monden OriginalPaper Pages: 35 - 41
Correlation of three-dimensional magnetic resonance imaging with precise histopathological map concerning carcinoma extension in the breast Goro AmanoNoriaki OhuchiSusumu Satomi OriginalPaper Pages: 43 - 55
Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer D.W. van ToornJ.W.R NortierJ.B. Vermorken OriginalPaper Pages: 57 - 62
Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene Utha Hellmann-BlumbergTracy L. TarasMichael W. DeGregorio OriginalPaper Pages: 63 - 70
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice Zsuzsanna KahánZsuzsanna KahánGábor Halmos OriginalPaper Pages: 71 - 79
Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations H. NaundorfB. Jost-ReuhlI. Fichtner OriginalPaper Pages: 81 - 92